UnitedHealth (UNH) Reports Q4 Earnings: What Key Metrics Have to Say
Werte in diesem Artikel
UnitedHealth Group (UNH) reported $100.81 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 6.8%. EPS of $6.81 for the same period compares to $6.16 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $102.25 billion, representing a surprise of -1.41%. The company delivered an EPS surprise of +1.49%, with the consensus EPS estimate being $6.71.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how UnitedHealth performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: UnitedHealthcare Customer Profile - People Served - Total UnitedHealthcare - Medical: 50.68 million compared to the 50.36 million average estimate based on five analysts. UnitedHealthcare Customer Profile - People Served - Total Commercial - Domestic: 29.73 million versus 29.7 million estimated by five analysts on average. UnitedHealthcare Customer Profile - People Served - Commercial - Domestic- Risk-based: 8.85 million versus the five-analyst average estimate of 8.87 million. UnitedHealthcare Customer Profile - People Served - Commercial - Domestic- Fee-based: 20.89 million versus 20.83 million estimated by five analysts on average. Revenues- Investment and other income: $1.55 billion versus $1.21 billion estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a +31.6% change. Revenues- Products: $13.48 billion compared to the $13.04 billion average estimate based on 10 analysts. The reported number represents a change of +19.1% year over year. Revenues- Services: $9.30 billion versus $9.37 billion estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a +6.8% change. Revenues- Premiums: $76.48 billion compared to the $78.16 billion average estimate based on 10 analysts. The reported number represents a change of +4.5% year over year. Revenues- Optum Insight: $4.78 billion compared to the $5.10 billion average estimate based on six analysts. The reported number represents a change of -0.1% year over year. Revenues- Optum Rx: $35.77 billion versus $35.34 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +14.8% change. Revenues- Optum Health: $25.66 billion versus $27.28 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +4.6% change. Revenues- UnitedHealthcare- Total: $74.13 billion compared to the $75.52 billion average estimate based on six analysts. The reported number represents a change of +4.7% year over year. View all Key Company Metrics for UnitedHealth here>>>Shares of UnitedHealth have returned +8.7% over the past month versus the Zacks S&P 500 composite's -1.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf Q4
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Q4
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu UnitedHealth Inc.
Analysen zu UnitedHealth Inc.
Datum | Rating | Analyst | |
---|---|---|---|
14.04.2022 | UnitedHealth Outperform | RBC Capital Markets | |
15.10.2020 | UnitedHealth Outperform | Credit Suisse Group | |
14.10.2020 | UnitedHealth Outperform | RBC Capital Markets | |
29.08.2019 | UnitedHealth Outperform | Credit Suisse Group | |
17.07.2018 | UnitedHealth buy | Goldman Sachs Group Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
14.04.2022 | UnitedHealth Outperform | RBC Capital Markets | |
15.10.2020 | UnitedHealth Outperform | Credit Suisse Group | |
14.10.2020 | UnitedHealth Outperform | RBC Capital Markets | |
29.08.2019 | UnitedHealth Outperform | Credit Suisse Group | |
17.07.2018 | UnitedHealth buy | Goldman Sachs Group Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
09.11.2016 | UnitedHealth Group Neutral | Mizuho | |
31.03.2011 | UnitedHealth Group perform | Oppenheimer & Co. Inc. | |
08.02.2011 | UnitedHealth Group neutral | Goldman Sachs Group Inc. | |
15.11.2010 | UnitedHealth Group hold | Stifel, Nicolaus & Co., Inc. | |
20.04.2010 | UnitedHealth neutral | Wedbush Morgan Securities Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
11.06.2009 | UnitedHealth underperform | Oppenheimer & Co. Inc. |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für UnitedHealth Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen